spot_img
27 C
Miami
HomeUncategorizedA new intranasal vaccine technology could create immunity against covid-19 and HIV

A new intranasal vaccine technology could create immunity against covid-19 and HIV

The new method offers a “promising approach” to replace less effective intramuscular injections.

A group of US academics has published a study in the journal Science Translational Medicine on a new intranasal vaccination platform that can transport immunizing proteins through the surface of mucous membranes and create antibodies to HIV and SARS-CoV-2.

Vaccines are usually injected into the muscle, but viruses such as human immunodeficiency, which attack the immune system, or that of covid-19, affect organisms through the mucous membranes.

These membranes are the main objective of the new technology, which has achieved an intense antibody reaction against these viruses in experiments with mice and non-human primates. The method provides a “promising approach” for administering vaccines through the nose and other linings of the mucosa instead of traditional injections, according to the research team, led by Brittany Hartwell, of the Massachusetts Institute of Technology (MIT, for its acronym in English).

The essence of technology The logic is in the use of amph proteins, which consist of viral proteins conjugated to a blood protein called albumin. This albumin interacts with a neonatal receptor to be transported across the mucosal surface.

The amph protein can be formulated based on the Env gp120 protein, which exists in the structures of HIV and the SARS-Cov2 and which is responsible for binding to human cells.

After administering the vaccine intranasally to mice and macaques, high concentrations of antibodies were recorded in various mucosal tissue protectors, such as immunoglobulins G and A.

Intranasal vaccines can elicit stronger antibody responses, the immune system’s protectors, than traditional injections. However, the studies carried out to date have not obtained satisfactory results when it comes to achieving vaccine uptake through the mucosal surface.

Exploring the clinical implications of the study, the scientist Francis Szoka, from the University of California, indicated that these results could be “a good omen for the possibility of a vaccine to prevent infection by HIV and have the potential to contribute to the creation of a vaccine against SARS-CoV- 2 regardless of the variant“.

spot_img

latest articles

explore more

error: Content is protected !!